3 Hospital and Life Science Stocks With a Strong Future Roadmap: Park Medi World, Sai Life Sciences and Gujarat Kidney & Super Speciality
- October 7, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Park Medi World Rs 274.85, P/E 39.89. Sai Life Rs 1,558.10, P/E 91.42. Gujarat Kidney Rs 193.62, P/E 91.23. Closing prices of 6 Oct 2026.
Quick Answer
Hospital and life science stocks with the clearest long-term roadmaps today include Park Medi World in multi-speciality hospitals in North India, Sai Life Sciences in drug discovery, development and manufacturing services for global pharma firms and Gujarat Kidney & Super Speciality in kidney care and super-speciality hospital services. FY26 revenue growth was 20.0% at Park Medi World, 29.5% at Sai Life and 105.2% at Gujarat Kidney. P/E stands at 39.89 for Park Medi World (industry 62.73), 91.42 for Sai Life (industry 37.19) and 91.23 for Gujarat Kidney (industry 62.73). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Hospital and life science stocks give investors exposure to regional hospital chains and research services firms that serve patients and global drug makers. Results depend on bed occupancy, patient volumes and pharma customer orders, which is why capacity use matters as much as headline growth.
This list covers three hospital and drug development stocks: Park Medi World for multi-speciality hospitals in North India, Sai Life Sciences for drug discovery, development and manufacturing services for global pharma firms and Gujarat Kidney & Super Speciality for kidney care and super-speciality hospital services. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital and Life Science Stocks?
Hospital and life science stocks are shares of companies that run hospitals or provide drug discovery, development and manufacturing services. Results depend on bed occupancy, patient mix, customer orders, capacity use and operating margin, so full beds and long customer contracts separate the stronger names.
Hospital and Life Science Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three hospital and life science stocks as of the 6 October 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Park Medi World | 274.85 | 11,837 | 39.89 | 62.73 | 12.77% | 0.18 |
| Sai Life Sciences | 1,558.10 | 33,071 | 91.42 | 37.19 | 14.05% | 0.12 |
| Gujarat Kidney & Super Speciality | 193.62 | 1,525 | 91.23 | 62.73 | 6.14% | 0.12 |
Among hospital and drug development stocks, Park Medi World trades below the industry P/E, while Sai Life and Gujarat Kidney trade at a premium to the industry multiple.
Why Do Hospital and Life Science Stocks Have a Strong Roadmap in India?
Hospital and life science stocks have a strong roadmap in India because healthcare spending is rising, regional cities need more beds and global pharma firms are moving more research and manufacturing work to Indian partners. Three drivers stand out.
- Rising healthcare spending: More insured and higher-income households use hospitals.
- Regional bed shortage: Smaller cities need more quality hospital capacity.
- Outsourced drug development: Global pharma firms use Indian research and manufacturing partners.
Park Medi World: Multi-Speciality Hospitals in North India Anchor the Roadmap
Park Medi World’s roadmap rests on multi-speciality hospitals in North India, with new beds and higher patient volumes supporting revenue.
Revenue grew from Rs 1,093.96 crore in FY22 to Rs 1,710.96 crore in FY26, a 56.4% rise, and FY26 revenue was 20.0% higher than FY25. FY26 net profit rose 27.0% to Rs 273.56 crore. Over four years, net profit rose from Rs 199.38 crore in FY22 to Rs 273.56 crore. In Q1 FY27, revenue grew 19.1% to Rs 483.36 crore, and net profit rose 35.2% to Rs 88.59 crore. Operating margin was 28.46% in FY26 and 28.11% in Q1 FY27 against 28.03% a year earlier.
Debt to equity is 0.18 and return on equity is 12.77%. FY26 operating cash flow was Rs 329.09 crore against capital expenditure of Rs 119.69 crore. At a P/E of 39.89 against an industry P/E of 62.73, the stock trades below its industry multiple.
What to watch: Return on equity of 12.77% is modest.
Sai Life Sciences: Drug Discovery and Development Services Drive the Pipeline
Sai Life’s roadmap rests on drug discovery, development and manufacturing services for global pharma firms, with new capacity and long customer ties supporting growth.
Revenue grew from Rs 897.74 crore in FY22 to Rs 2,241.62 crore in FY26, a 149.7% rise, and FY26 revenue was 29.5% higher than FY25. FY26 net profit rose 105.1% to Rs 348.91 crore. In Q1 FY27, revenue grew 10.2% to Rs 557.83 crore, and net profit rose 21.2% to Rs 73.29 crore. Operating margin was 30.74% in FY26 and 27.34% in Q1 FY27 against 26.36% a year earlier.
Debt to equity is 0.12 and return on equity is 14.05%. FY26 operating cash flow was Rs 509.13 crore against capital expenditure of Rs 592.96 crore. At a P/E of 91.42 against an industry P/E of 37.19, the stock trades above its industry multiple.
What to watch: FY26 capex of Rs 592.96 Cr was above operating cash flow of Rs 509.13 Cr, and Q1 FY27 net profit growth of 21.2% is well below the 105.1% of FY26. The P/E of 91.42 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.
Gujarat Kidney & Super Speciality: Kidney Care and Super-Speciality Services Build the Next Leg
Gujarat Kidney’s roadmap rests on kidney care and super-speciality hospital services, with new beds and more patients supporting growth.
FY26 revenue was Rs 82.89 crore, 105.2% higher than FY25. FY26 net profit rose 76.9% to Rs 16.81 crore. In Q1 FY27, revenue grew 129.1% to Rs 34.98 crore, and net profit fell 1.5% to Rs 5.32 crore. Operating margin was 33.91% in FY26 and 26.45% in Q1 FY27 against 56.55% a year earlier.
Debt to equity is 0.12 and return on equity is 6.14%. FY26 operating cash flow was negative at Rs 3.86 crore against capital expenditure of Rs 94.42 crore. At a P/E of 91.23 against an industry P/E of 62.73, the stock trades above its industry multiple.
What to watch: The Q1 FY27 operating margin of 26.45% was below the 56.55% of a year earlier, and the FY26 operating margin of 33.91% was below the 41.53% of FY25. Q1 FY27 net profit was 1.5% lower than a year earlier; the P/E of 91.23 sits above the industry P/E of 62.73, so earnings delivery matters for the valuation.
Best Hospital and Life Science Stocks in India: Park Medi World vs Sai Life vs Gujarat Kidney on Key Financials
Among the best hospital and life science stocks in India, Gujarat Kidney leads on FY26 operating margin and Q1 FY27 revenue growth; Sai Life leads on five-year revenue growth and return on equity; Park Medi World leads on the lowest P/E. The table puts the numbers side by side.
| Metric | Park Medi World | Sai Life | Gujarat Kidney |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,710.96 | 2,241.62 | 82.89 |
| FY26 revenue growth | 20.0% | 29.5% | 105.2% |
| FY26 net profit (Rs Cr) | 273.56 | 348.91 | 16.81 |
| FY26 net profit growth | 27.0% | 105.1% | 76.9% |
| FY26 operating profit margin | 28.46% | 30.74% | 33.91% |
| Q1 FY27 revenue growth (YoY) | 19.1% | 10.2% | 129.1% |
| Q1 FY27 net profit growth (YoY) | 35.2% | 21.2% | -1.5% |
| Return on equity | 12.77% | 14.05% | 6.14% |
| P/E ratio | 39.89 | 91.42 | 91.23 |
| Debt to equity | 0.18 | 0.12 | 0.12 |
| Dividend yield | 0.00% | 0.00% | 0.00% |
| FY26 operating cash flow (Rs Cr) | 329.09 | 509.13 | -3.86 |
Hospital and research earnings follow occupancy and customer orders, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Regional Hospital and Research Services Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen hospital and life science stocks and shortlist regional hospital and research services stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by stock.
- Track operating margin across several quarters, because input costs can move faster than prices.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these hospital and life science stocks
Risks to Consider Before Investing in Hospital and Life Science Stocks
- Valuation: Sai Life and Gujarat Kidney trade at 91.42 and 91.23 times earnings against industry multiples of 37.19 and 62.73.
- Cash flow: Gujarat Kidney had negative operating cash flow in FY26.
- Expansion spending: Sai Life’s FY26 capex was above its operating cash flow.
- Small size: Gujarat Kidney has a market cap of Rs 1,525 Cr, so its shares can swing sharply.
Download the Univest iOS App or Univest Android App to track Park Medi World, Sai Life and Gujarat Kidney live.
Final Take: Which Stock Has the Strongest Roadmap?
These three regional hospital and research services stocks cover multi-speciality hospitals, drug development services, and kidney care. Gujarat Kidney leads on FY26 operating margin and Q1 FY27 revenue growth; Sai Life leads on five-year revenue growth and return on equity; Park Medi World leads on the lowest P/E.
Across hospital and drug development stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the regional hospital and research services stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Hospital and Life Science Stocks
Which are the best hospital and life science stocks in India with a strong roadmap?
Ans. Park Medi World, Sai Life Sciences and Gujarat Kidney & Super Speciality stand out for their roadmaps in regional hospitals and drug development services. FY26 revenue growth was 20.0% at Park Medi World, 29.5% at Sai Life and 105.2% at Gujarat Kidney, and return on equity ranges from 6.14% to 14.05%.
Is Park Medi World a good stock to buy now?
Ans. Park Medi World has a debt to equity ratio of 0.18, a return on equity of 12.77% and a P/E of 39.89 against an industry P/E of 62.73. Valuation, cash flow and expansion spending move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Park Medi World, Sai Life and Gujarat Kidney?
Ans. The P/E ratio is 39.89 for Park Medi World (industry 62.73), 91.42 for Sai Life (industry 37.19) and 91.23 for Gujarat Kidney (industry 62.73). Only Sai Life and Gujarat Kidney trade at or above the industry multiple.
Which of these hospital and life science stocks has the highest return on equity?
Ans. Sai Life Sciences has the highest return on equity at 14.05%, followed by Park Medi World at 12.77% and Gujarat Kidney & Super Speciality at 6.14%.
What are the risks of investing in hospital and life science stocks?
Ans. The main risks are high valuations at two firms, negative operating cash flow at one, capex ahead of cash flow at another and small company size. Sai Life trades at 91.42 times earnings against an industry multiple of 37.19.
How did Park Medi World, Sai Life and Gujarat Kidney perform in Q1 FY27?
Ans. Park Medi World reported revenue of Rs 483.36 crore, up 19.1% year on year, and net profit rose 35.2% to Rs 88.59 crore. Sai Life Sciences reported revenue of Rs 557.83 crore, up 10.2% year on year, and net profit rose 21.2% to Rs 73.29 crore. Gujarat Kidney & Super Speciality reported revenue of Rs 34.98 crore, up 129.1% year on year, and net profit fell 1.5% to Rs 5.32 crore.
Do hospital and life science stocks pay dividends?
Ans. Dividend payouts differ across the three companies. The dividend yield is 0.00% for Park Medi World, 0.00% for Sai Life and 0.00% for Gujarat Kidney, based on dividends declared for FY26.
How can I invest in hospital and life science stocks in India?
Ans. You can buy hospital and life science stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.